Edwards Lifesciences Corp (NYSE:EW) VP Robert W.A. Sellers sold 12,020 shares of the business’s stock in a transaction dated Monday, February 5th. The shares were sold at an average price of $131.03, for a total transaction of $1,574,980.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Edwards Lifesciences Corp (NYSE:EW) opened at $123.78 on Friday. Edwards Lifesciences Corp has a 52-week low of $89.20 and a 52-week high of $138.48. The company has a market capitalization of $26,190.00, a PE ratio of 42.98, a PEG ratio of 1.88 and a beta of 0.63. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.41 and a current ratio of 1.81.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, February 1st. The medical research company reported $0.94 EPS for the quarter, topping the Zacks’ consensus estimate of $0.91 by $0.03. Edwards Lifesciences had a return on equity of 27.69% and a net margin of 18.11%. The business had revenue of $888.50 million during the quarter, compared to the consensus estimate of $868.45 million. During the same period in the previous year, the company posted $0.75 earnings per share. The business’s revenue for the quarter was up 15.7% on a year-over-year basis. research analysts predict that Edwards Lifesciences Corp will post 4.49 EPS for the current year.

Edwards Lifesciences declared that its Board of Directors has approved a share buyback program on Thursday, December 7th that authorizes the company to buyback $1.00 billion in shares. This buyback authorization authorizes the medical research company to purchase shares of its stock through open market purchases. Shares buyback programs are typically an indication that the company’s board believes its stock is undervalued.

Several institutional investors have recently made changes to their positions in EW. Koch Industries Inc. grew its position in shares of Edwards Lifesciences by 28,363.1% during the second quarter. Koch Industries Inc. now owns 1,397,254 shares of the medical research company’s stock worth $1,386,000 after buying an additional 1,392,345 shares in the last quarter. Atlantic Trust Group LLC grew its position in shares of Edwards Lifesciences by 734.7% during the third quarter. Atlantic Trust Group LLC now owns 914,989 shares of the medical research company’s stock worth $100,018,000 after buying an additional 805,370 shares in the last quarter. Janus Henderson Group PLC grew its position in shares of Edwards Lifesciences by 1,135.0% during the third quarter. Janus Henderson Group PLC now owns 619,703 shares of the medical research company’s stock worth $67,739,000 after buying an additional 569,525 shares in the last quarter. Old Mutual Global Investors UK Ltd. grew its position in shares of Edwards Lifesciences by 83.0% during the third quarter. Old Mutual Global Investors UK Ltd. now owns 1,100,885 shares of the medical research company’s stock worth $120,337,000 after buying an additional 499,436 shares in the last quarter. Finally, Wells Fargo & Company MN grew its position in shares of Edwards Lifesciences by 20.2% during the third quarter. Wells Fargo & Company MN now owns 2,548,282 shares of the medical research company’s stock worth $278,553,000 after buying an additional 429,022 shares in the last quarter. 81.52% of the stock is owned by institutional investors and hedge funds.

EW has been the subject of several research reports. Cowen reaffirmed a “buy” rating and issued a $135.00 target price on shares of Edwards Lifesciences in a research report on Thursday, October 12th. Canaccord Genuity reaffirmed a “buy” rating and issued a $135.00 target price (down from $155.00) on shares of Edwards Lifesciences in a research report on Wednesday, October 25th. SunTrust Banks set a $124.00 target price on Edwards Lifesciences and gave the company a “buy” rating in a research report on Wednesday, October 25th. Barclays dropped their target price on Edwards Lifesciences from $120.00 to $118.00 and set an “equal weight” rating for the company in a research report on Wednesday, October 25th. Finally, Morgan Stanley dropped their target price on Edwards Lifesciences from $133.00 to $120.00 and set an “overweight” rating for the company in a research report on Thursday, October 26th. Three research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company. Edwards Lifesciences currently has an average rating of “Buy” and a consensus target price of $141.15.

TRADEMARK VIOLATION NOTICE: “Insider Selling: Edwards Lifesciences Corp (EW) VP Sells 12,020 Shares of Stock” was originally published by Watch List News and is owned by of Watch List News. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of international trademark & copyright law. The correct version of this news story can be read at https://www.watchlistnews.com/insider-selling-edwards-lifesciences-corp-ew-vp-sells-12020-shares-of-stock/1854041.html.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Insider Buying and Selling by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.